BioSpace News Archive

FDA

Hugel Receives FDA Approval in the United States of Letybo (letibotulinumtoxinA-wlbg) for Injection for the Treatment of Glabellar Lines

Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults.

March 4, 2024
·
5 min read
BioForest

BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences

BioLife Solutions, Inc. today announced that Roderick de Greef , Chief Executive Officer, and Troy Wichterman, Chief Financial Officer, will present and meet with current and prospective investors at the following March Investor Conferences.

March 4, 2024
·
1 min read
Drug Development

Molecular Templates, Inc. Provides Interim Update

Molecular Templates, Inc. today provided an update on its programs.

March 4, 2024
·
9 min read
BioMidwest

MediView Announces Study Results Demonstrating High Registration and Targeting Accuracy of Augmented Reality-Based Navigational Guidance System

MediView XR, Inc., a leading clinical augmented reality (AR) med-tech company, announced today study results of its XR90 AR-based surgical visualization and navigation system, published recently in the Journal of Medical Imaging.

March 4, 2024
·
3 min read
Deals

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand’s Human Capital Management and Compensation Committee approved the grant of a non-qualified stock option award to purchase 15,100 shares of its common stock to one non-executive employee.

March 4, 2024
·
2 min read
BioMidwest

Aruna BIO Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic

Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative diseases, is pleased to announce the formation of its Stroke Advisory Board.

March 4, 2024
·
4 min read
Genetown

Vor Bio to Participate in Upcoming March 2024 Investor Conferences

Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.

March 4, 2024
·
1 min read
Business

Osmol Therapeutics Appoints Ron Weitzman, M.D., as Interim Chief Medical Officer

Osmol Therapeutics announced that it has appointed Ron Weitzman, M.D., as interim Chief Medical Officer, replacing Arthur DeCillis, M.D., who is joining Osmol’s Scientific Advisory Board.

March 4, 2024
·
2 min read
Biotech Bay

4DMT to Participate in Upcoming March 2024 Investor Conferences

4D Molecular Therapeutics, a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, announced that management will participate in fireside chats at upcoming investor conferences in March.

March 4, 2024
·
2 min read
Genetown

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Immuneering Corporation (Nasdaq: IMRX) today announced that management will participate in the Cowen 44th Annual Health Care Conference, which is taking place at the Marriott Copley Place in Boston from March 4-6, 2024, to discuss the company’s pipeline, platform, and business strategy.

March 4, 2024
·
1 min read